Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 21

1.

Mechanism-based approaches to treating fragile X.

Dölen G, Carpenter RL, Ocain TD, Bear MF.

Pharmacol Ther. 2010 Jul;127(1):78-93. doi: 10.1016/j.pharmthera.2010.02.008. Epub 2010 Mar 18. Review.

PMID:
20303363
2.

Design, synthesis, and evaluation of naphthalene-sulfonamide antagonists of human CCR8.

Jenkins TJ, Guan B, Dai M, Li G, Lightburn TE, Huang S, Freeze BS, Burdi DF, Jacutin-Porte S, Bennett R, Chen W, Minor C, Ghosh S, Blackburn C, Gigstad KM, Jones M, Kolbeck R, Yin W, Smith S, Cardillo D, Ocain TD, Harriman GC.

J Med Chem. 2007 Feb 8;50(3):566-84.

PMID:
17266208
3.

Regulation of IRAK-4 kinase activity via autophosphorylation within its activation loop.

Cheng H, Addona T, Keshishian H, Dahlstrand E, Lu C, Dorsch M, Li Z, Wang A, Ocain TD, Li P, Parsons TF, Jaffee B, Xu Y.

Biochem Biophys Res Commun. 2007 Jan 19;352(3):609-16. Epub 2006 Nov 21.

PMID:
17141195
4.

A selective small molecule IkappaB Kinase beta inhibitor blocks nuclear factor kappaB-mediated inflammatory responses in human fibroblast-like synoviocytes, chondrocytes, and mast cells.

Wen D, Nong Y, Morgan JG, Gangurde P, Bielecki A, Dasilva J, Keaveney M, Cheng H, Fraser C, Schopf L, Hepperle M, Harriman G, Jaffee BD, Ocain TD, Xu Y.

J Pharmacol Exp Ther. 2006 Jun;317(3):989-1001. Epub 2006 Mar 8.

PMID:
16525037
5.

Pharmacological characterization of guinea pig chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTH2).

Liu F, Gonzalo JA, Manning S, O'Connell LE, Fedyk ER, Burke KE, Elder AM, Pulido JC, Cao W, Tayber O, Qiu Y, Ghosh S, Ocain TD, Hodge MR, Suzuki-Yagawa Y.

Prostaglandins Other Lipid Mediat. 2005 May;76(1-4):133-47.

PMID:
15967168
6.

Nucleotide binding to CARD12 and its role in CARD12-mediated caspase-1 activation.

Lu C, Wang A, Wang L, Dorsch M, Ocain TD, Xu Y.

Biochem Biophys Res Commun. 2005 Jun 17;331(4):1114-9.

PMID:
15882992
7.

Participation of Rip2 in lipopolysaccharide signaling is independent of its kinase activity.

Lu C, Wang A, Dorsch M, Tian J, Nagashima K, Coyle AJ, Jaffee B, Ocain TD, Xu Y.

J Biol Chem. 2005 Apr 22;280(16):16278-83. Epub 2005 Feb 3.

8.

In vitro immunomodulatory activity of ruthenium complexes.

Newcomb JR, Rivnay B, Bastos CM, Ocain TD, Gordon K, Gregory P, Turci SM, Sterne KA, Jesson M, Krieger J, Jenson JC, Jones B.

Inflamm Res. 2003 Jun;52(6):263-71.

PMID:
12835898
9.

Novel small-molecule inhibitors of RNA polymerase III.

Wu L, Pan J, Thoroddsen V, Wysong DR, Blackman RK, Bulawa CE, Gould AE, Ocain TD, Dick LR, Errada P, Dorr PK, Parkinson T, Wood T, Kornitzer D, Weissman Z, Willis IM, McGovern K.

Eukaryot Cell. 2003 Apr;2(2):256-64.

10.

Substrate-based design of the first class of angiotensin-converting enzyme-related carboxypeptidase (ACE2) inhibitors.

Dales NA, Gould AE, Brown JA, Calderwood EF, Guan B, Minor CA, Gavin JM, Hales P, Kaushik VK, Stewart M, Tummino PJ, Vickers CS, Ocain TD, Patane MA.

J Am Chem Soc. 2002 Oct 9;124(40):11852-3.

PMID:
12358520
11.

Synthesis and immunosuppressive activity of ruthenium complexes.

Bastos CM, Gordon KA, Ocain TD.

Bioorg Med Chem Lett. 1998 Jan 20;8(2):147-50.

PMID:
9871643
12.

T-cell receptor ligation by peptide/MHC induces activation of a caspase in immature thymocytes: the molecular basis of negative selection.

Clayton LK, Ghendler Y, Mizoguchi E, Patch RJ, Ocain TD, Orth K, Bhan AK, Dixit VM, Reinherz EL.

EMBO J. 1997 May 1;16(9):2282-93.

13.

A novel series of low molecular weight immunosuppressive agents.

Ocain TD, Bastos CM, Gordon KA, Granstein RD, Jenson JC, Jones B, McAuliffe DJ, Newcomb JR.

Transplant Proc. 1996 Dec;28(6):3032-4. No abstract available.

PMID:
8962176
14.

Rapamycin: a novel immunosuppressive macrolide.

Sehgal SN, Molnar-Kimber K, Ocain TD, Weichman BM.

Med Res Rev. 1994 Jan;14(1):1-22. Review. No abstract available.

PMID:
8309312
15.

A nonimmunosuppressive triene-modified rapamycin analog is a potent inhibitor of peptidyl prolyl cis-trans isomerase.

Ocain TD, Longhi D, Steffan RJ, Caccese RG, Sehgal SN.

Biochem Biophys Res Commun. 1993 May 14;192(3):1340-6.

PMID:
7685167
16.

New modified heterocyclic phenylalanine derivatives. Incorporation into potent inhibitors of human renin.

Ocain TD, Deininger DD, Russo R, Senko NA, Katz A, Kitzen JM, Mitchell R, Oshiro G, Russo A, Stupienski R, et al.

J Med Chem. 1992 Mar 6;35(5):823-32.

PMID:
1548674
17.

alpha-Keto amide inhibitors of aminopeptidases.

Ocain TD, Rich DH.

J Med Chem. 1992 Feb 7;35(3):451-6.

PMID:
1738140
18.
19.

L-lysinethiol: a subnanomolar inhibitor of aminopeptidase B.

Ocain TD, Rich DH.

Biochem Biophys Res Commun. 1987 Jun 30;145(3):1038-42.

PMID:
3111463
20.

Amino acid derived latent isocyanates: irreversible inactivation of porcine pancreatic elastase and human leukocyte elastase.

Groutas WC, Abrams WR, Theodorakis MC, Kasper AM, Rude SA, Badger RC, Ocain TD, Miller KE, Moi MK, Brubaker MJ, et al.

J Med Chem. 1985 Feb;28(2):204-9.

PMID:
3844034
21.

Mechanism-based inhibitors of elastase.

Groutas WC, Badger RC, Ocain TD, Felker D, Frankson J, Theodorakis M.

Biochem Biophys Res Commun. 1980 Aug 29;95(4):1890-4. No abstract available.

PMID:
6903133

Supplemental Content

Loading ...
Support Center